{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:33:01Z","timestamp":1792801981641,"version":"4.5.0"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":69,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82302062"],"award-info":[{"award-number":["82302062"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82473313"],"award-info":[{"award-number":["82473313"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Xiang An Innovation Laboratory Science and Technology Plan Project","award":["2023XAKJ0101019"],"award-info":[{"award-number":["2023XAKJ0101019"]}]},{"name":"the Natural Science Foundation of Xiamen, China","award":["3502Z20227165"],"award-info":[{"award-number":["3502Z20227165"]}]},{"name":"the Fundamental Research Funds for the Central Universities","award":["20720220006"],"award-info":[{"award-number":["20720220006"]}]},{"name":"the National Key Research and Development Program of China","award":["2024YFC2310401"],"award-info":[{"award-number":["2024YFC2310401"]}]},{"name":"Xiamen Industry-Academia-Research Projects","award":["2024CXY0113"],"award-info":[{"award-number":["2024CXY0113"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-026-01465-1","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T13:35:00Z","timestamp":1778333700000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["LNP-based delivery of a Toll-like receptor 9 agonist elicits potent adjuvant effects and antitumor immunity"],"prefix":"10.1038","volume":"11","author":[{"given":"Yarong","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renfei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingbing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningshao","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaowei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"key":"1465_CR1","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jconrel.2021.11.022","volume":"341","author":"JR Melamed","year":"2022","unstructured":"Melamed, J. R. et al. Lipid nanoparticle chemistry determines how nucleoside base modifications alter mRNA delivery. J. Control. Release 341, 206\u2013214 (2022).","journal-title":"J. Control. Release"},{"key":"1465_CR2","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1038\/s42003-021-02441-2","volume":"4","author":"MJ Carrasco","year":"2021","unstructured":"Carrasco, M. J. et al. Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration. Commun. Biol. 4, 956 (2021).","journal-title":"Commun. Biol."},{"key":"1465_CR3","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jconrel.2019.04.025","volume":"303","author":"N Wang","year":"2019","unstructured":"Wang, N., Chen, M. & Wang, T. Liposomes used as a vaccine adjuvant-delivery system: from basics to clinical immunization. J. Control. Release 303, 130\u2013150 (2019).","journal-title":"J. Control. Release"},{"key":"1465_CR4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.nano.2014.11.003","volume":"11","author":"G Caracciolo","year":"2015","unstructured":"Caracciolo, G. Liposome-protein corona in a physiological environment: challenges and opportunities for targeted delivery of nanomedicines. Nanomedicine 11, 543\u2013557 (2015).","journal-title":"Nanomedicine"},{"key":"1465_CR5","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1021\/acs.bioconjchem.0c00366","volume":"31","author":"V Francia","year":"2020","unstructured":"Francia, V., Schiffelers, R. M., Cullis, P. R. & Witzigmann, D. The biomolecular corona of lipid nanoparticles for gene therapy. Bioconjug. Chem. 31, 2046\u20132059 (2020).","journal-title":"Bioconjug. Chem."},{"key":"1465_CR6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s43586-022-00104-y","volume":"2","author":"BB Mendes","year":"2022","unstructured":"Mendes, B. B. et al. Nanodelivery of nucleic acids. Nat. Rev. Methods Prim. 2, 24 (2022).","journal-title":"Nat. Rev. Methods Prim."},{"key":"1465_CR7","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.mimet.2019.03.017","volume":"160","author":"V Dave","year":"2019","unstructured":"Dave, V. et al. Lipid-polymer hybrid nanoparticles: synthesis strategies and biomedical applications. J. Microbiol. Methods 160, 130\u2013142 (2019).","journal-title":"J. Microbiol. Methods"},{"key":"1465_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2025.101463","volume":"33","author":"S Xu","year":"2025","unstructured":"Xu, S., Hu, Z., Song, F., Xu, Y. & Han, X. Lipid nanoparticles: composition, formulation, and application. Mol. Ther. Methods Clin. Dev. 33, 101463 (2025).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1465_CR9","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41392-022-01007-w","volume":"7","author":"S Qin","year":"2022","unstructured":"Qin, S. et al. mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct. Target. Ther. 7, 166 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1465_CR10","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41568-025-00820-z","volume":"25","author":"N Zaidi","year":"2025","unstructured":"Zaidi, N., Jaffee, E. M. & Yarchoan, M. Recent advances in therapeutic cancer vaccines. Nat. Rev. Cancer 25, 517\u2013533 (2025).","journal-title":"Nat. Rev. Cancer"},{"key":"1465_CR11","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.immuni.2013.07.004","volume":"39","author":"K Palucka","year":"2013","unstructured":"Palucka, K. & Banchereau, J. Dendritic-cell-based therapeutic cancer vaccines. Immunity 39, 38\u201348 (2013).","journal-title":"Immunity"},{"key":"1465_CR12","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41570-020-00244-3","volume":"5","author":"C Pifferi","year":"2021","unstructured":"Pifferi, C., Fuentes, R. & Fern\u00e1ndez-Tejada, A. Natural and synthetic carbohydrate-based vaccine adjuvants and their mechanisms of action. Nat. Rev. Chem. 5, 197\u2013216 (2021).","journal-title":"Nat. Rev. Chem."},{"key":"1465_CR13","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1016\/j.vaccine.2019.04.055","volume":"37","author":"S Shi","year":"2019","unstructured":"Shi, S. et al. Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity. Vaccine 37, 3167\u20133178 (2019).","journal-title":"Vaccine"},{"key":"1465_CR14","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1080\/14760584.2023.2238807","volume":"22","author":"Y Zeng","year":"2023","unstructured":"Zeng, Y., Zou, F., Xia, N. & Li, S. In-depth review of delivery carriers associated with vaccine adjuvants: current status and future perspectives. Expert Rev. Vaccines 22, 681\u2013695 (2023).","journal-title":"Expert Rev. Vaccines"},{"key":"1465_CR15","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.ado5937","volume":"10","author":"E Ben-Akiva","year":"2025","unstructured":"Ben-Akiva, E., Chapman, A., Mao, T. & Irvine, D. J. Linking vaccine adjuvant mechanisms of action to function. Sci. Immunol. 10, eado5937 (2025).","journal-title":"Sci. Immunol."},{"key":"1465_CR16","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1080\/14760584.2024.2382725","volume":"23","author":"F Roman","year":"2024","unstructured":"Roman, F. et al. Adjuvant system AS01: from mode of action to effective vaccines. Expert Rev. Vaccines 23, 715\u2013729 (2024).","journal-title":"Expert Rev. Vaccines"},{"key":"1465_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-017-0027-3","volume":"2","author":"M Coccia","year":"2017","unstructured":"Coccia, M. et al. Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFN\u03b3 response promoting vaccine immunogenicity. NPJ Vaccines 2, 25 (2017).","journal-title":"NPJ Vaccines"},{"key":"1465_CR18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/ni.1863","volume":"11","author":"T Kawai","year":"2010","unstructured":"Kawai, T. & Akira, S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11, 373\u2013384 (2010).","journal-title":"Nat. Immunol."},{"key":"1465_CR19","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3390\/pharmaceutics14020423","volume":"14","author":"JX Yang","year":"2022","unstructured":"Yang, J. X. et al. Recent advances in the development of toll-like receptor agonist-based vaccine adjuvants for infectious diseases. Pharmaceutics 14, 423 (2022).","journal-title":"Pharmaceutics"},{"key":"1465_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1089\/nat.2018.0751","volume":"29","author":"MJ Lange","year":"2019","unstructured":"Lange, M. J., Burke, D. H. & Chaput, J. C. Activation of innate immune responses by a CpG oligonucleotide sequence composed entirely of threose nucleic acid. Nucleic Acid Ther. 29, 51\u201359 (2019).","journal-title":"Nucleic Acid Ther."},{"key":"1465_CR21","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/ni.3123","volume":"16","author":"A Iwasaki","year":"2015","unstructured":"Iwasaki, A. & Medzhitov, R. Control of adaptive immunity by the innate immune system. Nat. Immunol. 16, 343\u2013353 (2015).","journal-title":"Nat. Immunol."},{"key":"1465_CR22","doi-asserted-by":"publisher","first-page":"5340","DOI":"10.1021\/acsnano.2c08429","volume":"17","author":"L Yang","year":"2023","unstructured":"Yang, L. et al. Engineered toll-like receptor nanoagonist binding to extracellular matrix elicits safe and robust antitumor immunity. ACS Nano 17, 5340\u20135353 (2023).","journal-title":"ACS Nano"},{"key":"1465_CR23","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/S1471-4914(01)02264-X","volume":"8","author":"S Agrawal","year":"2002","unstructured":"Agrawal, S. & Kandimalla, E. R. Medicinal chemistry and therapeutic potential of CpG DNA. Trends Mol. Med. 8, 114\u2013121 (2002).","journal-title":"Trends Mol. Med"},{"key":"1465_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-15178-y","volume":"7","author":"J Pohar","year":"2017","unstructured":"Pohar, J. et al. Phosphodiester backbone of the CpG motif within immunostimulatory oligodeoxynucleotides augments activation of Toll-like receptor 9. Sci. Rep. 7, 14598 (2017).","journal-title":"Sci. Rep."},{"key":"1465_CR25","doi-asserted-by":"publisher","first-page":"50592","DOI":"10.1021\/acsami.2c15644","volume":"14","author":"D Qiao","year":"2022","unstructured":"Qiao, D., Li, L., Liu, L. & Chen, Y. Universal and translational nanoparticulate CpG adjuvant. ACS Appl. Mater. Interfaces 14, 50592\u201350600 (2022).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"1465_CR26","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41573-024-00977-6","volume":"23","author":"PR Cullis","year":"2024","unstructured":"Cullis, P. R. & Felgner, P. L. The 60-year evolution of lipid nanoparticles for nucleic acid delivery. Nat. Rev. Drug Discov. 23, 709\u2013722 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1465_CR27","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","volume":"25","author":"PR Cullis","year":"2017","unstructured":"Cullis, P. R. & Hope, M. J. Lipid nanoparticle systems for enabling gene therapies. Mol. Ther. 25, 1467\u20131475 (2017).","journal-title":"Mol. Ther."},{"key":"1465_CR28","first-page":"1","volume":"16","author":"DS Tretiakova","year":"2022","unstructured":"Tretiakova, D. S. & Vodovozova, E. L. Liposomes as adjuvants and vaccine delivery systems. Biochem (Mosc.) Suppl. Ser. A Membr. Cell Biol. 16, 1\u201320 (2022).","journal-title":"Biochem (Mosc.) Suppl. Ser. A Membr. Cell Biol."},{"key":"1465_CR29","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3390\/pharmaceutics13020206","volume":"13","author":"BN Aldosari","year":"2021","unstructured":"Aldosari, B. N., Alfagih, I. M. & Almurshedi, A. S. Lipid nanoparticles as delivery systems for RNA-based vaccines. Pharmaceutics 13, 206 (2021).","journal-title":"Pharmaceutics"},{"key":"1465_CR30","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1039\/C6CS00636A","volume":"46","author":"S Behzadi","year":"2017","unstructured":"Behzadi, S. et al. Cellular uptake of nanoparticles: journey inside the cell. Chem. Soc. Rev. 46, 4218\u20134244 (2017).","journal-title":"Chem. Soc. Rev."},{"key":"1465_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2024.115304","volume":"209","author":"Y Tang","year":"2024","unstructured":"Tang, Y. et al. Interactions between nanoparticles and lymphatic systems: mechanisms and applications in drug delivery. Adv. Drug Deliv. Rev. 209, 115304 (2024).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"1465_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.103479","volume":"24","author":"S Ndeupen","year":"2021","unstructured":"Ndeupen, S. et al. The mRNA-LNP platform\u2019s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience 24, 103479 (2021).","journal-title":"iScience"},{"key":"1465_CR33","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41590-022-01160-y","volume":"23","author":"S Tahtinen","year":"2022","unstructured":"Tahtinen, S. et al. IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nat. Immunol. 23, 532\u2013542 (2022).","journal-title":"Nat. Immunol."},{"key":"1465_CR34","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.immuni.2022.05.007","volume":"55","author":"MG Alameh","year":"2022","unstructured":"Alameh, M. G. et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity 55, 1136\u20131138 (2022).","journal-title":"Immunity"},{"key":"1465_CR35","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","volume":"8","author":"T Zhao","year":"2023","unstructured":"Zhao, T. et al. Vaccine adjuvants: mechanisms and platforms. Signal Transduct. Target. Ther. 8, 283 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1465_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120586","volume":"601","author":"L Schoenmaker","year":"2021","unstructured":"Schoenmaker, L. et al. mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. Int J. Pharm. 601, 120586 (2021).","journal-title":"Int J. Pharm."},{"key":"1465_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202301687","volume":"12","author":"Z Zhong","year":"2023","unstructured":"Zhong, Z. et al. Lipid nanoparticle delivery alters the adjuvanticity of the TLR9 agonist CpG by innate immune activation in lymphoid tissue. Adv. Health. Mater. 12, e2301687 (2023).","journal-title":"Adv. Health. Mater."},{"key":"1465_CR38","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jconrel.2005.06.014","volume":"107","author":"J Heyes","year":"2005","unstructured":"Heyes, J., Palmer, L., Bremner, K. & MacLachlan, I. Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J. Control. Release 107, 276\u2013287 (2005).","journal-title":"J. Control. Release"},{"key":"1465_CR39","doi-asserted-by":"publisher","first-page":"21733","DOI":"10.1039\/C9NR09347H","volume":"11","author":"JA Kulkarni","year":"2019","unstructured":"Kulkarni, J. A., Witzigmann, D., Leung, J., Tam, Y. Y. C. & Cullis, P. R. On the role of helper lipids in lipid nanoparticle formulations of siRNA. Nanoscale 11, 21733\u201321739 (2019).","journal-title":"Nanoscale"},{"key":"1465_CR40","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1016\/j.biomaterials.2010.01.065","volume":"31","author":"C He","year":"2010","unstructured":"He, C., Hu, Y., Yin, L., Tang, C. & Yin, C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 31, 3657\u20133666 (2010).","journal-title":"Biomaterials"},{"key":"1465_CR41","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/j.ymthe.2018.03.010","volume":"26","author":"S Sabnis","year":"2018","unstructured":"Sabnis, S. et al. A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates. Mol. Ther. 26, 1509\u20131519 (2018).","journal-title":"Mol. Ther."},{"key":"1465_CR42","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1006\/mthe.2002.0631","volume":"6","author":"ML Forrest","year":"2002","unstructured":"Forrest, M. L. & Pack, D. W. On the kinetics of polyplex endocytic trafficking: implications for gene delivery vector design. Mol. Ther. 6, 57\u201366 (2002).","journal-title":"Mol. Ther."},{"key":"1465_CR43","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nbt.2614","volume":"31","author":"G Sahay","year":"2013","unstructured":"Sahay, G. et al. Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat. Biotechnol. 31, 653\u2013658 (2013).","journal-title":"Nat. Biotechnol."},{"key":"1465_CR44","doi-asserted-by":"publisher","first-page":"18440","DOI":"10.1021\/jp303267y","volume":"116","author":"AK Leung","year":"2012","unstructured":"Leung, A. K. et al. Lipid nanoparticles containing siRNA synthesized by microfluidic mixing exhibit an electron-dense nanostructured core. J. Phys. Chem. C Nanomater Interfaces 116, 18440\u201318450 (2012).","journal-title":"J. Phys. Chem. C Nanomater Interfaces"},{"key":"1465_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-023-01989-x","volume":"21","author":"A He","year":"2023","unstructured":"He, A. et al. Nanovaccine-based strategies for lymph node targeted delivery and imaging in tumor immunotherapy. J. Nanobiotechnol. 21, 236 (2023).","journal-title":"J. Nanobiotechnol."},{"key":"1465_CR46","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1600-065X.2008.00589.x","volume":"221","author":"ML Dustin","year":"2008","unstructured":"Dustin, M. L. T-cell activation through immunological synapses and kinapses. Immunol. Rev. 221, 77\u201389 (2008).","journal-title":"Immunol. Rev."},{"key":"1465_CR47","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/nnano.2012.207","volume":"7","author":"MP Monopoli","year":"2012","unstructured":"Monopoli, M. P., Aberg, C., Salvati, A. & Dawson, K. A. Biomolecular coronas provide the biological identity of nanosized materials. Nat. Nanotechnol. 7, 779\u2013786 (2012).","journal-title":"Nat. Nanotechnol."},{"key":"1465_CR48","doi-asserted-by":"publisher","first-page":"C723","DOI":"10.1152\/ajpcell.00462.2010","volume":"300","author":"KW Dunn","year":"2011","unstructured":"Dunn, K. W., Kamocka, M. M. & McDonald, J. H. A practical guide to evaluating colocalization in biological microscopy. Am. J. Physiol. Cell Physiol. 300, C723\u2013C742 (2011).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"1465_CR49","first-page":"101121","volume":"21","author":"X Lin","year":"2026","unstructured":"Lin, X. et al. The evolution of lipid nanoparticles: paving the way for next-generation nucleic acid medicines. Asian J. Pharm. Sci. 21, 101121 (2026).","journal-title":"Asian J. Pharm. Sci."},{"key":"1465_CR50","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/nri3254","volume":"12","author":"OP Joffre","year":"2012","unstructured":"Joffre, O. P., Segura, E., Savina, A. & Amigorena, S. Cross-presentation by dendritic cells. Nat. Rev. Immunol. 12, 557\u2013569 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"1465_CR51","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0092-8674(01)00449-4","volume":"106","author":"I Mellman","year":"2001","unstructured":"Mellman, I. & Steinman, R. M. Dendritic cells: specialized and regulated antigen processing machines. Cell 106, 255\u2013258 (2001).","journal-title":"Cell"},{"key":"1465_CR52","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1182\/blood-2002-11-3355","volume":"102","author":"E Bourke","year":"2003","unstructured":"Bourke, E., Bosisio, D., Golay, J., Polentarutti, N. & Mantovani, A. The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood 102, 956\u2013963 (2003).","journal-title":"Blood"},{"key":"1465_CR53","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","volume":"31","author":"S Spranger","year":"2017","unstructured":"Spranger, S., Dai, D., Horton, B. & Gajewski, T. F. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell 31, 711\u2013723.e4 (2017).","journal-title":"Cancer Cell"},{"key":"1465_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1259989","volume":"14","author":"M Kou","year":"2023","unstructured":"Kou, M. & Wang, L. Surface toll-like receptor 9 on immune cells and its immunomodulatory effect. Front Immunol. 14, 1259989 (2023).","journal-title":"Front Immunol."},{"key":"1465_CR55","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/ni1028","volume":"5","author":"E Latz","year":"2004","unstructured":"Latz, E. et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat. Immunol. 5, 190\u2013198 (2004).","journal-title":"Nat. Immunol."},{"key":"1465_CR56","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1084\/jem.20060401","volume":"203","author":"C Guiducci","year":"2006","unstructured":"Guiducci, C. et al. Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation. J. Exp. Med. 203, 1999\u20132008 (2006).","journal-title":"J. Exp. Med."},{"key":"1465_CR57","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/35047123","volume":"408","author":"H Hemmi","year":"2000","unstructured":"Hemmi, H. et al. A Toll-like receptor recognizes bacterial DNA. Nature 408, 740\u2013745 (2000).","journal-title":"Nature"},{"key":"1465_CR58","doi-asserted-by":"publisher","first-page":"6518","DOI":"10.1093\/nar\/gkw236","volume":"44","author":"RL Juliano","year":"2016","unstructured":"Juliano, R. L. The delivery of therapeutic oligonucleotides. Nucleic Acids Res 44, 6518\u20136548 (2016).","journal-title":"Nucleic Acids Res"},{"key":"1465_CR59","doi-asserted-by":"publisher","first-page":"7297","DOI":"10.1073\/pnas.92.16.7297","volume":"92","author":"O Boussif","year":"1995","unstructured":"Boussif, O. et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. USA 92, 7297\u20137301 (1995).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1465_CR60","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou, X., Zaks, T., Langer, R. & Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078\u20131094 (2021).","journal-title":"Nat. Rev. Mater."},{"key":"1465_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2025.101518","volume":"33","author":"CA Brimacombe","year":"2025","unstructured":"Brimacombe, C. A. et al. Rational design of lipid nanoparticles for enabling gene therapies. Mol. Ther. Methods Clin. Dev. 33, 101518 (2025).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1465_CR62","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41591-020-0753-3","volume":"26","author":"TJ Moyer","year":"2020","unstructured":"Moyer, T. J. et al. Engineered immunogen binding to alum adjuvant enhances humoral immunity. Nat. Med. 26, 430\u2013440 (2020).","journal-title":"Nat. Med."},{"key":"1465_CR63","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1016\/S0264-410X(02)00169-X","volume":"20","author":"H HogenEsch","year":"2002","unstructured":"HogenEsch, H. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine 20, S34\u2013S39 (2002).","journal-title":"Vaccine"},{"key":"1465_CR64","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.cell.2020.09.040","volume":"183","author":"A Iwasaki","year":"2020","unstructured":"Iwasaki, A. & Omer, S. B. Why and how vaccines work. Cell 183, 290\u2013295 (2020).","journal-title":"Cell"},{"key":"1465_CR65","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2025.2517137","volume":"32","author":"G Sinani","year":"2025","unstructured":"Sinani, G. & \u015eenel, S. Advances in vaccine adjuvant development and future perspectives. Drug Deliv. 32, 2517137 (2025).","journal-title":"Drug Deliv."},{"key":"1465_CR66","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nri2510","volume":"9","author":"P Marrack","year":"2009","unstructured":"Marrack, P., McKee, A. S. & Munks, M. W. Towards an understanding of the adjuvant action of aluminium. Nat. Rev. Immunol. 9, 287\u2013293 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"1465_CR67","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3390\/pharmaceutics13040455","volume":"13","author":"KC Petkar","year":"2021","unstructured":"Petkar, K. C. et al. An overview of nanocarrier-based adjuvants for vaccine delivery. Pharmaceutics 13, 455 (2021).","journal-title":"Pharmaceutics"},{"key":"1465_CR68","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jconrel.2018.04.041","volume":"282","author":"R Kuai","year":"2018","unstructured":"Kuai, R. et al. Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy. J. Control. Release 282, 131\u2013139 (2018).","journal-title":"J. Control. Release"},{"key":"1465_CR69","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi, N. et al. mRNA vaccines\u2014a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261\u2013279 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1465_CR70","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3390\/vaccines9020074","volume":"9","author":"R Keikha","year":"2021","unstructured":"Keikha, R., Daliri, K. & Jebali, A. The use of nanobiotechnology in immunology and vaccination. Vaccines 9, 74 (2021).","journal-title":"Vaccines"},{"key":"1465_CR71","first-page":"26","volume":"2","author":"KD Moudgil","year":"2000","unstructured":"Moudgil, K. D. & Sercarz, E. E. The self-directed T cell repertoire: its creation and activation. Rev. Immunogenet 2, 26\u201337 (2000).","journal-title":"Rev. Immunogenet"},{"key":"1465_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-025-03423-w","volume":"23","author":"S Zhang","year":"2025","unstructured":"Zhang, S. et al. Immunogenicity and cellular response of a herpes zoster virus gEgI fusion protein adjuvanted with CpG-emulsion in mice. J. Nanobiotechnol. 23, 395 (2025).","journal-title":"J. Nanobiotechnol."},{"key":"1465_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108216","volume":"101","author":"L He","year":"2021","unstructured":"He, L. et al. Immune response of C57BL\/6J mice to herpes zoster subunit vaccines formulated with nanoemulsion-based and liposome-based adjuvants. Int Immunopharmacol. 101, 108216 (2021).","journal-title":"Int Immunopharmacol."},{"key":"1465_CR74","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","volume":"375","author":"AL Cunningham","year":"2016","unstructured":"Cunningham, A. L. et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N. Engl. J. Med. 375, 1019\u20131032 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1465_CR75","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13192","volume":"55","author":"Y Shen","year":"2022","unstructured":"Shen, Y. et al. Homotypic targeting of immunomodulatory nanoparticles for enhanced peripheral and central immunity. Cell Prolif. 55, e13192 (2022).","journal-title":"Cell Prolif."},{"key":"1465_CR76","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser, K. E. & Joyce, J. A. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell 41, 374\u2013403 (2023).","journal-title":"Cancer Cell"},{"key":"1465_CR77","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/intimm\/dxac012","volume":"34","author":"B Temizoz","year":"2022","unstructured":"Temizoz, B. et al. Anti-tumor immunity by transcriptional synergy between TLR9 and STING activation. Int. Immunol. 34, 353\u2013364 (2022).","journal-title":"Int. Immunol."},{"key":"1465_CR78","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/s41565-023-01447-7","volume":"18","author":"P Dosta","year":"2023","unstructured":"Dosta, P. et al. Investigation of the enhanced antitumour potency of STING agonist after conjugation to polymer nanoparticles. Nat. Nanotechnol. 18, 1351\u20131363 (2023).","journal-title":"Nat. Nanotechnol."},{"key":"1465_CR79","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ccell.2026.01.020","volume":"44","author":"X Sun","year":"2026","unstructured":"Sun, X., Park, M. D., Merad, M. & Brown, B. D. Macrophages: targets for next-generation cancer immunotherapy. Cancer Cell 44, 498\u2013518 (2026).","journal-title":"Cancer Cell"},{"key":"1465_CR80","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1586\/14760584.2015.966696","volume":"14","author":"KY Shen","year":"2015","unstructured":"Shen, K. Y., Chang, L. S., Leng, C. H. & Liu, S. J. Self-adjuvanting lipoimmunogens for therapeutic HPV vaccine development: potential clinical impact. Expert Rev. Vaccines 14, 383\u2013394 (2015).","journal-title":"Expert Rev. Vaccines"},{"key":"1465_CR81","doi-asserted-by":"publisher","DOI":"10.1186\/s13027-021-00346-7","volume":"16","author":"F Dorostkar","year":"2021","unstructured":"Dorostkar, F. et al. Co-administration of 2'3\u2019-cGAMP STING activator and CpG-C adjuvants with a mutated form of HPV 16 E7 protein leads to tumor growth inhibition in the mouse model. Infect. Agent Cancer 16, 7 (2021).","journal-title":"Infect. Agent Cancer"},{"key":"1465_CR82","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn3464","volume":"15","author":"J Ramos da Silva","year":"2023","unstructured":"Ramos da Silva, J. et al. Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice. Sci. Transl. Med. 15, eabn3464 (2023).","journal-title":"Sci. Transl. Med."},{"key":"1465_CR83","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.coi.2020.08.008","volume":"65","author":"SG Reed","year":"2020","unstructured":"Reed, S. G., Tomai, M. & Gale, M. J. Jr. New horizons in adjuvants for vaccine development. Curr. Opin. Immunol. 65, 97\u2013101 (2020).","journal-title":"Curr. Opin. Immunol."},{"key":"1465_CR84","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1515\/BC.2007.061","volume":"388","author":"O Boehm","year":"2007","unstructured":"Boehm, O. et al. Clinical chemistry reference database for Wistar rats and C57\/BL6 mice. Biol. Chem. 388, 547\u2013554 (2007).","journal-title":"Biol. Chem."},{"key":"1465_CR85","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/s41565-024-01615-3","volume":"19","author":"YC Zeng","year":"2024","unstructured":"Zeng, Y. C. et al. Fine tuning of CpG spatial distribution with DNA origami for improved cancer vaccination. Nat. Nanotechnol. 19, 1055\u20131065 (2024).","journal-title":"Nat. Nanotechnol."},{"key":"1465_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1112750","volume":"14","author":"M Li","year":"2023","unstructured":"Li, M., Zhao, C., Zhao, Y., Li, J. & Wei, L. Immunogenicity, efficacy, and safety of human papillomavirus vaccine: data from China. Front Immunol. 14, 1112750 (2023).","journal-title":"Front Immunol."},{"key":"1465_CR87","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","volume":"30","author":"JJ Ott","year":"2012","unstructured":"Ott, J. J., Stevens, G. A., Groeger, J. & Wiersma, S. T. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 30, 2212\u20132219 (2012).","journal-title":"Vaccine"},{"key":"1465_CR88","doi-asserted-by":"publisher","first-page":"349","DOI":"10.5582\/bst.2020.03267","volume":"14","author":"C Sun","year":"2020","unstructured":"Sun, C. & Xu, S. Advances in personalized neoantigen vaccines for cancer immunotherapy. Biosci. Trends 14, 349\u2013353 (2020).","journal-title":"Biosci. Trends"},{"key":"1465_CR89","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","volume":"21","author":"M Saxena","year":"2021","unstructured":"Saxena, M., van der Burg, S. H., Melief, C. J. M. & Bhardwaj, N. Therapeutic cancer vaccines. Nat. Rev. Cancer 21, 360\u2013378 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"1465_CR90","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41586-018-0810-y","volume":"565","author":"N Hilf","year":"2019","unstructured":"Hilf, N. et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 565, 240\u2013245 (2019).","journal-title":"Nature"},{"key":"1465_CR91","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 541, 321\u2013330 (2017).","journal-title":"Nature"},{"key":"1465_CR92","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","volume":"183","author":"PA Ott","year":"2020","unstructured":"Ott, P. A. et al. A Phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell 183, 347\u2013362.e24 (2020).","journal-title":"Cell"},{"key":"1465_CR93","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41551-018-0236-8","volume":"2","author":"CB Rodell","year":"2018","unstructured":"Rodell, C. B. et al. TLR7\/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. Nat. Biomed. Eng. 2, 578\u2013588 (2018).","journal-title":"Nat. Biomed. Eng."},{"key":"1465_CR94","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.3389\/fimmu.2019.03018","volume":"10","author":"S Shirai","year":"2020","unstructured":"Shirai, S. et al. Lipid nanoparticles potentiate CpG-oligodeoxynucleotide-based vaccine for influenza virus. Front. Immunol. 10, 3018 (2020).","journal-title":"Front. Immunol."},{"key":"1465_CR95","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0014-4827(84)90698-0","volume":"150","author":"MJ Geisow","year":"1984","unstructured":"Geisow, M. J. Fluorescein conjugates as indicators of subcellular pH: a critical evaluation. Exp. Cell Res. 150, 29\u201335 (1984).","journal-title":"Exp. Cell Res."},{"key":"1465_CR96","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nrd2059","volume":"5","author":"AM Krieg","year":"2006","unstructured":"Krieg, A. M. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5, 471\u2013484 (2006).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1465_CR97","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.2147\/IJN.S36111","volume":"7","author":"E Fr\u00f6hlich","year":"2012","unstructured":"Fr\u00f6hlich, E. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int. J. Nanomed. 7, 5577\u20135591 (2012).","journal-title":"Int. J. Nanomed."},{"key":"1465_CR98","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/nature14138","volume":"520","author":"U Ohto","year":"2015","unstructured":"Ohto, U. et al. Structural basis of CpG and inhibitory DNA recognition by Toll-like receptor 9. Nature 520, 702\u2013705 (2015).","journal-title":"Nature"},{"key":"1465_CR99","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51411-9","volume":"15","author":"S Kim","year":"2024","unstructured":"Kim, S. et al. Innate immune responses against mRNA vaccine promote cellular immunity through IFN-\u03b2 at the injection site. Nat. Commun. 15, 7226 (2024).","journal-title":"Nat. Commun."},{"key":"1465_CR100","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1517\/17425247.2011.558081","volume":"8","author":"M Henriksen-Lacey","year":"2011","unstructured":"Henriksen-Lacey, M., Korsholm, K. S., Andersen, P., Perrie, Y. & Christensen, D. Liposomal vaccine delivery systems. Expert Opin. Drug Deliv. 8, 505\u2013519 (2011).","journal-title":"Expert Opin. Drug Deliv."},{"key":"1465_CR101","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202402678","volume":"11","author":"Z Liu","year":"2024","unstructured":"Liu, Z. et al. A multi-functional nanoadjuvant coupling manganese with toll-like 9 agonist stimulates potent innate and adaptive anti-tumor immunity. Adv. Sci. 11, e2402678 (2024).","journal-title":"Adv. Sci."},{"key":"1465_CR102","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1230893","volume":"14","author":"J Zhang","year":"2023","unstructured":"Zhang, J. et al. Nanoparticle-based drug delivery systems to enhance cancer immunotherapy in solid tumors. Front. Immunol. 14, 1230893 (2023).","journal-title":"Front. Immunol."},{"key":"1465_CR103","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jconrel.2024.10.069","volume":"376","author":"T Li","year":"2024","unstructured":"Li, T. et al. Anti-CTLA-4 antibody self-presented dendritic cell nanovesicles boost the immunotherapy of hepatocellular carcinoma after microwave ablation. J. Control. Release 376, 913\u2013929 (2024).","journal-title":"J. Control. Release"},{"key":"1465_CR104","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41392-025-02191-1","volume":"10","author":"H Li","year":"2025","unstructured":"Li, H. et al. Intranasal prime-boost RNA vaccination elicits potent T cell response for lung cancer therapy. Signal Transduct. Target. Ther. 10, 101 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1465_CR105","doi-asserted-by":"publisher","first-page":"30701","DOI":"10.1021\/acsnano.4c09902","volume":"18","author":"Z Luo","year":"2024","unstructured":"Luo, Z. et al. Spleen-targeted mRNA vaccine doped with manganese adjuvant for robust anticancer immunity in vivo. ACS Nano 18, 30701\u201330715 (2024).","journal-title":"ACS Nano"},{"key":"1465_CR106","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58523-w","volume":"16","author":"MHY Cheng","year":"2025","unstructured":"Cheng, M. H. Y. et al. Liposomal lipid nanoparticles for extrahepatic delivery of mRNA. Nat. Commun. 16, 4135 (2025).","journal-title":"Nat. Commun."},{"key":"1465_CR107","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50093-7","volume":"15","author":"K Su","year":"2024","unstructured":"Su, K. et al. Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation. Nat. Commun. 15, 5659 (2024).","journal-title":"Nat. Commun."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01465-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01465-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01465-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:02:45Z","timestamp":1784286165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01465-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":107,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1465"],"URL":"https:\/\/doi.org\/10.1038\/s41541-026-01465-1","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"3 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"149"}}